Ginkgo Bioworks Holdings, Inc. (DNA): who owns it and who trades it
As of Nov 16, 2026, DNA insiders reported 19 open-market sales worth $3.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason R Kelly (Director), with $1.8M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ginkgo Bioworks Holdings
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DNA
182 funds and institutions reported DNA shares worth $363M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $42.4M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.28M | – | $42.4M | +18% |
| Viking Global Investors LP | 3.58M | – | $35.4M | No change |
| Erste Asset Management GmbH | 2.54M | – | $25.9M | +30% |
| Baillie Gifford & Co | 2.39M | – | $23.7M | No change |
| Vanguard Capital Management LLC | 2.09M | – | $20.7M | +9% |
| Anchorage Capital Group, L.L.C. | 1.75M | – | $17.3M | No change |
| Legal & General Group Plc | 1.67M | – | $16.5M | +0% |
| State Street Corp | 1.47M | – | $14.6M | +9% |
| Geode Capital Management, LLC | 1.22M | – | $12.1M | +21% |
| Forbes J M & Co LLP | 999,911 | – | $9.9M | -3% |
| Vanguard Portfolio Management LLC | 937,803 | – | $9.3M | +66% |
| Allianz Asset Management GmbH | 785,798 | – | $7.8M | +12% |
| UBS Group AG | 691,659 | – | $6.9M | +19% |
| Millennium Management LLC | 638,676 | – | $6.3M | +31% |
| AQR Capital Management LLC | 621,625 | – | $6.2M | +111% |
| Sb Investment Advisers (uk) Ltd | 610,729 | – | $6.1M | No change |
| Goldman Sachs Group Inc | 607,376 | – | $6M | -35% |
| Bank of America Corp | 545,852 | – | $5.4M | +14% |
| Prescott Group Capital Management, L.L.C. | 541,845 | – | $5.4M | No change |
| Renaissance Technologies LLC | 539,856 | – | $5.3M | +437% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DNA insiders reported $0 of open-market purchases and $3.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Barry Canton | 10% owner | Sale | 18,803 | $10.14 | $191K | Form 4 |
| Oct 19, 2026 | Barry Canton | 10% owner | Sale | 22,369 | $10.14 | $227K | Form 4 |
| Oct 19, 2026 | Steven P. Coen | See remarks | Sale | 766 | $10.14 | $7.8K | Form 4 |
| Oct 19, 2026 | Jason R Kelly | Director | Sale | 45,682 | $10.14 | $463K | Form 4 |
| Oct 5, 2026 | Steven P. Coen | See remarks | Sale | 2,403 | $15.00 | $36K | Form 4 |
| Sep 15, 2026 | Christian O Henry | Director | Sale | 5,000 | $7.08 | $35.4K | Form 4 |
| Aug 24, 2026 | Steven P. Coen | See remarks | Sale | 330 | $6.98 | $2.3K | Form 4 |
| Jul 17, 2026 | Steven P. Coen | See remarks | Sale | 752 | $7.90 | $5.9K | Form 4 |
| May 22, 2026 | Steven P. Coen | See remarks | Sale | 307 | $8.33 | $2.6K | Form 4 |
| Apr 17, 2026 | Steven P. Coen | See remarks | Sale | 324 | $7.95 | $2.6K | Form 4 |
| Apr 13, 2026 | Steven P. Coen | See remarks | Sale | 33,171 | $6.41 | $213K | Form 4 |
| Apr 10, 2026 | Barry Canton | 10% owner | Sale | 124,727 | $6.43 | $802K | Form 4 |
| Apr 9, 2026 | Reshma P. Shetty | Director | Sale | 13,116 | $6.40 | $83.9K | Form 4 |
| Apr 9, 2026 | Jason R Kelly | Director | Sale | 109,767 | $6.40 | $703K | Form 4 |
| Apr 8, 2026 | Reshma P. Shetty | Director | Sale | 13,155 | $6.93 | $91.2K | Form 4 |
| Apr 8, 2026 | Jason R Kelly | Director | Sale | 97,015 | $6.93 | $672K | Form 4 |
| Mar 16, 2026 | Steven P. Coen | See remarks | Sale | 708 | $6.74 | $4.8K | Form 4 |
| Jan 20, 2026 | Steven P. Coen | See remarks | Sale | 972 | $8.92 | $8.7K | Form 4 |
| Dec 15, 2025 | Steven P. Coen | See remarks | Sale | 736 | $8.89 | $6.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jason R Kelly | See remarks, Director | – | $1.8M | Oct 19, 2026 |
| Barry Canton | 10% owner | – | $1.2M | Oct 19, 2026 |
| Steven P. Coen | See remarks | – | $290K | Oct 19, 2026 |
| Reshma P. Shetty | See remarks, Director, 10% owner | – | $175K | Apr 9, 2026 |
| Christian O Henry | Director | – | $35.4K | Sep 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DNA short interest
9.49M DNA shares are sold short. Over the last 12 reports the number of shares short went up 110%.
As of Oct 30, 2026, 9.49M DNA shares were sold short, up 14.4% from the report before. At the average daily volume of 2.46M shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.49M | – | +14% | 2.46M | 3.9 |
| Oct 15, 2026 | 8.29M | – | +13% | 4.41M | 1.9 |
| Sep 30, 2026 | 7.32M | – | +2% | 2.74M | 2.7 |
| Sep 15, 2026 | 7.17M | – | +4% | 994,763 | 7.2 |
| Aug 31, 2026 | 6.87M | – | +23% | 1.25M | 5.5 |
| Aug 14, 2026 | 5.60M | – | +5% | 1.32M | 4.2 |
| Jul 31, 2026 | 5.32M | – | +2% | 797,215 | 6.7 |
| Jul 15, 2026 | 5.21M | – | +1% | 1.05M | 5.0 |
| Jun 30, 2026 | 5.16M | – | +5% | 1.28M | 4.0 |
| Jun 15, 2026 | 4.91M | – | +8% | 1.48M | 3.3 |
| May 29, 2026 | 4.56M | – | +1% | 932,929 | 4.9 |
| May 15, 2026 | 4.52M | – | -14% | 1.65M | 2.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ginkgo Bioworks Holdings company events
Ginkgo Bioworks Holdings filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 29, 2026AnnouncementShared information with investors. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 7, 2026DealGinkgo Bioworks, Inc., a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. completed the previously announced transaction with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. pursuant to the Stock Purchase Agreement, dated as of February 26, 2026, by and among the Seller, the… Filing
- Feb 27, 2026AgreementGinkgo Bioworks, Inc., a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc., entered into a Stock Purchase Agreement with Tower Biosecurity, Inc. and Ginkgo Biosecurity, LLC. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 23, 2025LeadershipGinkgo Bioworks Holdings, Inc. announced that Dr. Reshma Shetty, the Company’s President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly, the Company’s Chief Executive Officer, on January 1, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ginkgo Bioworks Holdings financials
Famous investors that hold DNA
5 of the 50 well-known investors we track reported holding DNA in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $37.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 2.90M | $37.2M | 0.1% | -19% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 637,053 | $8.2M | 0.0% | +18% |
| Israel Englander · Millennium Management | Q3 2026 | 559,478 | $7.2M | 0.0% | -12% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 399,614 | $5.1M | 0.0% | +19% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 218,724 | $2.8M | 0.0% | +67% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DNA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Cascade Investment, L.L.C. | 13G/A | 6.2% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 5.4% |
| Nov 16, 2026 | Cascade Investment, L.L.C. | 13G/A | 6.2% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 5.4% |
Questions about Ginkgo Bioworks Holdings, Inc. (DNA) stock
Who owns the most DNA stock?
The largest reported owner of Ginkgo Bioworks Holdings, Inc. (DNA) is BlackRock, Inc.. In total, 182 funds and institutions reported holding DNA at the end of Q2 2026. See the largest owners.
Are DNA insiders buying or selling?
In the last 12 months, DNA insiders reported no open-market purchases and 19 sales worth $3.6M. The latest trade was on Oct 19, 2026. See every trade.
What is the short interest in DNA?
As of Oct 30, 2026, 9.49M DNA shares were sold short, up 14.4% from the report before. At the average daily volume of 2.46M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold DNA?
5 of the 50 well-known investors we track reported DNA in their latest 13F filing, including Andreas Halvorsen, Jim Simons, Israel Englander. The largest position is worth $37.2M. See all holders.
Executive pay
Ginkgo Bioworks Holdings's chief executive was paid a total of $5.7M for the year ended Dec 31, 2025, up 364% from $1.2M the year before. In the last 12 months, Ginkgo Bioworks Holdings's executives and directors bought no stock on the open market and sold $2.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.